Capital7 Invests in Leading Biotech Firm Allied BioScience to Support Growth, Company's Portfolio Expansion
Capital7 Invests in Leading Biotech Firm Allied BioScience to Support Growth, Company's Portfolio Expansion News provided by Share this article Allied BioScience, maker of revolutionary residual antiviral surface coating Capital7, LLC has made an early stage investment in its Series C Preferred Stock. "After substantial due diligence, the Capital7 team decided to utilize our venture capital arm to invest in this exciting new patented chemical technology. Allied Bioscience represents a huge growth opportunity to provide consumers and industries such as mass transportation, sports, gaming and...